Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C22H21ClN2O8.C7H6O6S |
Molecular Weight | 695.048 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)C1=CC(=CC=C1O)S(O)(=O)=O.[H][C@@]23[C@@H](O)[C@]4([H])C(=C)C5=C(Cl)C=CC(O)=C5C(=O)C4=C(O)[C@]2(O)C(=O)C(C(N)=O)=C(O)[C@H]3N(C)C
InChI
InChIKey=FYSVKUUNXYGFLA-CCHMMTNSSA-N
InChI=1S/C22H21ClN2O8.C7H6O6S/c1-6-9-7(23)4-5-8(26)11(9)16(27)12-10(6)17(28)14-15(25(2)3)18(29)13(21(24)32)20(31)22(14,33)19(12)30;8-6-2-1-4(14(11,12)13)3-5(6)7(9)10/h4-5,10,14-15,17,26,28-30,33H,1H2,2-3H3,(H2,24,32);1-3,8H,(H,9,10)(H,11,12,13)/t10-,14-,15+,17+,22+;/m1./s1
Molecular Formula | C22H21ClN2O8 |
Molecular Weight | 476.864 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 4 / 5 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Molecular Formula | C7H6O6S |
Molecular Weight | 218.184 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Meclocycline is a tetracycline antibiotic. It is used topically for skin infections treatment. Tetracyclines are broad-spectrum bacteriostatic agents and act by inhibiting protein synthesis by blocking the binding of aminoacyl tRNA (transfer RNA) to the mRNA (messenger RNA) ribosome complex. Meclocycline might increase sensitivity to light when it is used with Aminolevulinic acid.
Originator
Approval Year
Doses
Dose | Population | Adverse events |
---|---|---|
1 % 2 times / day multiple, topical Recommended Dose: 1 %, 2 times / day Route: topical Route: multiple Dose: 1 %, 2 times / day Sources: Page: p.177 |
unhealthy, 12-37 n = 33 Health Status: unhealthy Condition: Acne vulgaris Age Group: 12-37 Sex: M+F Population Size: 33 Sources: Page: p.177 |
Other AEs: Yellow skin... |
1 % 2 times / day multiple, topical Recommended Dose: 1 %, 2 times / day Route: topical Route: multiple Dose: 1 %, 2 times / day Sources: |
unhealthy |
Other AEs: Contact dermatitis... |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Yellow skin | 6% | 1 % 2 times / day multiple, topical Recommended Dose: 1 %, 2 times / day Route: topical Route: multiple Dose: 1 %, 2 times / day Sources: Page: p.177 |
unhealthy, 12-37 n = 33 Health Status: unhealthy Condition: Acne vulgaris Age Group: 12-37 Sex: M+F Population Size: 33 Sources: Page: p.177 |
Contact dermatitis | 1 % 2 times / day multiple, topical Recommended Dose: 1 %, 2 times / day Route: topical Route: multiple Dose: 1 %, 2 times / day Sources: |
unhealthy |
Sample Use Guides
In Vivo Use Guide
Curator's Comment: Noticeable improvement may be seen in 4 to 6 weeks. In some patients it may require up to 6 to 8 weeks of treatment before noticeable improvement is seen and up to 8 to 12 weeks before maximum benefit is seen.
Two times a day, morning and evening.
Route of Administration:
Topical
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:15:30 GMT 2023
by
admin
on
Fri Dec 15 15:15:30 GMT 2023
|
Record UNII |
46VZA7RX2B
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C1595
Created by
admin on Fri Dec 15 15:15:30 GMT 2023 , Edited by admin on Fri Dec 15 15:15:30 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1377508
Created by
admin on Fri Dec 15 15:15:30 GMT 2023 , Edited by admin on Fri Dec 15 15:15:30 GMT 2023
|
PRIMARY | |||
|
DBSALT002414
Created by
admin on Fri Dec 15 15:15:30 GMT 2023 , Edited by admin on Fri Dec 15 15:15:30 GMT 2023
|
PRIMARY | |||
|
46VZA7RX2B
Created by
admin on Fri Dec 15 15:15:30 GMT 2023 , Edited by admin on Fri Dec 15 15:15:30 GMT 2023
|
PRIMARY | |||
|
73816-42-9
Created by
admin on Fri Dec 15 15:15:30 GMT 2023 , Edited by admin on Fri Dec 15 15:15:30 GMT 2023
|
PRIMARY | |||
|
CHEMBL261772
Created by
admin on Fri Dec 15 15:15:30 GMT 2023 , Edited by admin on Fri Dec 15 15:15:30 GMT 2023
|
PRIMARY | |||
|
C47596
Created by
admin on Fri Dec 15 15:15:30 GMT 2023 , Edited by admin on Fri Dec 15 15:15:30 GMT 2023
|
PRIMARY | |||
|
SUB03105MIG
Created by
admin on Fri Dec 15 15:15:30 GMT 2023 , Edited by admin on Fri Dec 15 15:15:30 GMT 2023
|
PRIMARY | |||
|
DTXSID5045596
Created by
admin on Fri Dec 15 15:15:30 GMT 2023 , Edited by admin on Fri Dec 15 15:15:30 GMT 2023
|
PRIMARY | |||
|
277-614-2
Created by
admin on Fri Dec 15 15:15:30 GMT 2023 , Edited by admin on Fri Dec 15 15:15:30 GMT 2023
|
PRIMARY | |||
|
100000086163
Created by
admin on Fri Dec 15 15:15:30 GMT 2023 , Edited by admin on Fri Dec 15 15:15:30 GMT 2023
|
PRIMARY | |||
|
757831
Created by
admin on Fri Dec 15 15:15:30 GMT 2023 , Edited by admin on Fri Dec 15 15:15:30 GMT 2023
|
PRIMARY | |||
|
203162
Created by
admin on Fri Dec 15 15:15:30 GMT 2023 , Edited by admin on Fri Dec 15 15:15:30 GMT 2023
|
PRIMARY | RxNorm | ||
|
m7119
Created by
admin on Fri Dec 15 15:15:30 GMT 2023 , Edited by admin on Fri Dec 15 15:15:30 GMT 2023
|
PRIMARY | Merck Index |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE | |||
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |